Mounjaro

Mounjaro tiredness gets glossed over in the prescribing information, which lists fatigue at roughly 4 to 6 percent across the SURPASS trial program.

Six-month tirzepatide weight loss averages roughly 12 to 18 percent of starting body weight at the higher maintenance doses (10 to 15 mg weekly).

Yes. Tirzepatide is FDA-approved for chronic weight management in non-diabetic adults under the brand name Zepbound.

Introduction Tirzepatide (Zepbound® for obesity, Mounjaro® for diabetes) is currently the most effective FDA-approved weight loss medication, with 20.9% body weight reduction at 72…

Tirzepatide is the best obesity drug currently approved. It produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (Jastreboff et al.

Introduction Patients switch between tirzepatide formulations and other GLP-1 drugs for several reasons: insurance changes, cost, side effect tolerance, plateau on the current drug,…

Tirzepatide is a peptide that degrades when exposed to heat, light, freezing, or repeated agitation.

Tirzepatide’s side effect profile is dominated by gastrointestinal effects: nausea, vomiting, diarrhea, constipation, and reflux.

Most patients feel reduced hunger within 3-7 days of their first 2.5mg injection. Visible scale movement usually starts in week 2 or 3.